4. MPG-Novelle: Die klinische Forschung mit Medizinprodukten und die neue Sponsor-Definition

Veröffentlichungen

• 3. Mai

  2022

  Amgen Inc. v. Sanofi: Does the Supreme Court’s Call for the Solicitor General’s Views Signal an Intention to Resolve Important Enablement Questions for Genus Claims?

  Immuno-Innovation Blog
• 20. April

  2022

  Does PTAB’s Ex Parte Cellect Decision Endanger Biopharmaceutical Patent Terms?

• 18. April

  2022

  Does the PTAB’s Recent Ex Parte Cellect Decision Signal Concern for the Valuable Patent Terms of Biopharmaceuticals?

  Immuno-Innovation Blog